drugset
drugset / Trial / NCT04639310

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

NCT04639310 ↗

Phase 3 Terminated 8 enrolled Xenon Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).

Timeline

Start
2021-03-29
Primary completion
2023-05-16
Completion
2023-05-16

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision; Not a safety decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezogabine Small molecule 21 mg/kg Oral

Indications

epilepsy syndrome